Phibro Animal Health Corporation (PAHC) — Fair Value Analysis
Base-case fair value (P50): $43.67 · Current price: $43.85 · Verdict: Fairly Valued
The Verdict on PAHC
Based on comprehensive Monte Carlo simulations, PHIBRO ANIMAL HEALTH CORP CLASS A (PAHC) is currently Fairly Valued. The analysis indicates that PAHC's current price of $43.85 sits remarkably close to its median fair value (P50) of $43.67, representing a marginal -0.4% difference. This tight alignment suggests the market price accurately reflects the company's intrinsic value as determined by thousands of forward-looking scenarios. Investors seeking a clear directional bias for PAHC based purely on its median fair value will find little immediate discrepancy to exploit.
How PAHC stacks up against peers
PAHC's operational and financial health is categorized as an "average" quality tier relative to its sector peers. This assessment suggests that while the company maintains a stable footing, it doesn't exhibit significant differentiating strengths or weaknesses that would warrant a substantial premium or discount compared to its industry. The "average" quality tier, combined with the minimal -0.4% deviation between the current price of $43.85 and the P50 fair value of $43.67, reinforces the "Fairly Valued" verdict. This indicates that PAHC is largely performing and being valued in line with general sector expectations.
What this means for investors
For investors considering PAHC, the "Fairly Valued" verdict, with the current price of $43.85 just -0.4% from the P50 fair value of $43.67, implies that the stock is not presenting an obvious valuation-driven opportunity for aggressive entry or exit based on the median outcome. While the median fair value suggests equilibrium, investors should also consider potential downside scenarios and bull cases, which may present different pictures of future value. Understanding PAHC's "average" quality tier helps contextualize its current standing. For a deeper dive into PAHC's full Monte Carlo fair value distribution, including bear (P10) and bull (P90) target prices and the probability of upside, sign up for a free FairCurve account. This will also allow you to track PAHC's fair value as new fundamental data is released.
Frequently Asked Questions
Is PAHC overvalued or undervalued right now?
Based on Monte Carlo simulations, PHIBRO ANIMAL HEALTH CORP CLASS A (PAHC) is Fairly Valued. Its current price of $43.85 is just slightly above the median fair value (P50) of $43.67.
What is the bear case and bull case for PAHC?
The full Monte Carlo distribution, including bear (P10) and bull (P90) target prices and the probability of upside, is available with a free FairCurve account. We do not provide specific dollar values here.
How does FairCurve calculate PAHC's fair value?
FairCurve calculates PAHC's fair value using Monte Carlo simulations, running thousands of forward-looking scenarios to determine a probabilistic range of outcomes for the company's intrinsic value.
How can I track PAHC's fair value as it changes?
You can add PAHC to a free FairCurve watchlist to receive daily fair-value updates. FairCurve will instantly re-value PAHC whenever new earnings or significant fundamental data are released.